-
1.发明授权公开(公告)号：US10308704B2
公开(公告)日：2019-06-04
申请号：US15004375
申请日：2016-01-22
Applicant: Amgen Inc.
Inventor： Jeonghoon Sun , Lei-Ting Tony Tam , Mark Leo Michaels , Thomas Charles Boone , Rohini Deshpande , Yue-Sheng Li , Huiquan Han
IPC: C07K14/71 , C07K14/495 , A61K38/00
Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
-
公开(公告)号：US20160244497A1
公开(公告)日：2016-08-25
申请号：US15007438
申请日：2016-01-27
Applicant: Amgen Inc.
Inventor： Kenneth W. WALKER , Colin V. Gegg, JR. , Randy I. Hecht , Edward J. Belouski , Yue-Sheng Li , Mark L. Michaels , Jing Xu , Murielle Marie Ellison
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
Abstract translation: 本发明提供编码FGF21突变体多肽，FGF21突变体多肽，包含FGF21突变体多肽的药物组合物的核酸分子，以及使用此类核酸，多肽或药物组合物治疗代谢紊乱的方法。
-
公开(公告)号：US20160168223A1
公开(公告)日：2016-06-16
申请号：US15004281
申请日：2016-01-22
Applicant: Amgen Inc.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
IPC: C07K14/50
CPC classification number: C07K14/50 , A61K38/00 , A61K38/1825 , A61K2039/505 , C07K16/18 , C07K2319/30
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
Abstract translation: 本发明提供编码FGF21突变体多肽，FGF21突变体多肽，包含FGF21突变体多肽的药物组合物的核酸分子，以及使用此类核酸，多肽或药物组合物治疗代谢紊乱的方法。
-
公开(公告)号：US20250136653A1
公开(公告)日：2025-05-01
申请号：US18737435
申请日：2024-06-07
Applicant: AMGEN INC.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
公开(公告)号：US20240076333A1
公开(公告)日：2024-03-07
申请号：US18499499
申请日：2023-11-01
Applicant: Amgen Inc.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , JIng Xu
CPC classification number: C07K14/50 , A61K38/1825 , A61K2039/505
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
Patent Agency Ranking
公开(公告)号：US10189912B2
公开(公告)日：2019-01-29
申请号：US15405233
申请日：2017-01-12
Applicant: AMGEN INC.
Inventor： Kenneth W. Walker , Yue-Sheng Li , Thomas Charles Boone , George Doellgast , HoSung Min , Jane Talvenheimo , Taruna Arora , Frederick W. Jacobsen
IPC: C07K16/44 , A61K39/395 , C07K16/00 , C07K16/18 , C07K14/435 , C07K14/575 , C07K14/605 , C07K16/24 , C07K14/66 , A61K47/68
Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.
-
公开(公告)号：US09562108B2
公开(公告)日：2017-02-07
申请号：US14285579
申请日：2014-05-22
Applicant: AMGEN INC.
Inventor： Kenneth W. Walker , Yue-Sheng Li , Thomas Charles Boone , HoSung Min , Jane Talvenheimo , Taruna Arora , Frederick W. Jacobsen
IPC: C07K16/44 , A61K39/395 , C07K16/00 , C07K16/18 , C07K14/435 , C07K14/575 , C07K14/605 , C07K16/24
CPC classification number: C07K16/44 , A61K39/39591 , A61K47/6817 , A61K47/6843 , C07K14/43504 , C07K14/575 , C07K14/605 , C07K14/66 , C07K16/00 , C07K16/18 , C07K16/248 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/30 , C07K2319/55
Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.
Abstract translation: 公开了分离的抗原结合蛋白，例如但不限于抗体或抗体片段。 还公开了包含抗原结合蛋白，编码它的分离的核酸，载体，宿主细胞和用于制备它的方法中的杂交瘤的药物组合物和药物。 在一些实施方案中，抗原结合蛋白包含与其结合的1-24个药理活性化学部分，例如药理学活性多肽。
-
公开(公告)号：US09273106B2
公开(公告)日：2016-03-01
申请号：US14134482
申请日：2013-12-19
Applicant: Amgen Inc.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC classification number: C07K14/50 , A61K38/00 , A61K38/1825 , A61K2039/505 , C07K16/18 , C07K2319/30
Abstract: The invention provides FGF21 mutant polypeptides with reduced proteolysis and aggregation, pharmaceutical compositions comprising the same.
Abstract translation: 本发明提供具有降低的蛋白水解和聚集的FGF21突变体多肽，其包含其的药物组合物。
-
公开(公告)号：US20190023757A1
公开(公告)日：2019-01-24
申请号：US15996232
申请日：2018-06-01
Applicant: AMGEN INC.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
公开(公告)号：US10011642B2
公开(公告)日：2018-07-03
申请号：US15004281
申请日：2016-01-22
Applicant: Amgen Inc.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC classification number: C07K14/50 , A61K38/00 , A61K38/1825 , A61K2039/505 , C07K16/18 , C07K2319/30
Abstract: The invention provides methods of treating diabetes, reducing triglyceride levels, and treating obesity by administering to a subject in need there a fusion protein comprising an FGF21 mutant.
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.032 seconds)
